78 filings
Page 2 of 4
8-K
vldow1y
18 May 22
AVROBIO Announces Preclinical Gene Therapy Data for Pompe Disease at American Society of Gene and Cell Therapy (ASGCT) annual meeting
8:30am
8-K
js5vfqc2f0jmpf8
17 May 22
AVROBIO Reports Positive Data from Phase 1/2 Clinical Trial of Investigational
7:12am
8-K
l7s3 xq7jb
10 May 22
AVROBIO Reports First Quarter 2022 Financial Results and Provides Business Update
7:05am
8-K
nabm30d6dcgd ii
17 Mar 22
AVROBIO Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides Business Update
7:54am
8-K
7c46ofhc 3z6p9p
9 Feb 22
AVROBIO Reports Interim Data from Phase 1/2 Clinical Trial
7:11am
8-K
z1bdp aqrr36m
7 Jan 22
Cost Associated with Exit or Disposal Activities
4:21pm
8-K
83bjc w4appc3xh0z5
4 Jan 22
Other Events
7:08am
8-K
2c12dy89k8jevt 64
4 Nov 21
AVROBIO Reports Third Quarter 2021 Financial Results and Provides Business Update
7:32am
8-K
qscznl82
19 Oct 21
AVROBIO Reports New Interim Safety Data Across Investigational Gene Therapies for Fabry and Gaucher Disease Type 1
7:15am
8-K
d1zxhqpt qq
9 Aug 21
Other Events
9:06am
8-K
dla uiz1s2nu5n
5 Aug 21
AVROBIO Reports Second Quarter 2021 Financial Results and Provides Business Update
7:28am
8-K
fq145ggkh4s 79ng1f
17 Jun 21
Other Events
8:17am
8-K
r19vp5hshhh
14 Jun 21
Submission of Matters to a Vote of Security Holders
4:30pm
8-K
e0h48ilvt8 h2ytz
13 May 21
AVROBIO Reports First Quarter 2021 Financial Results and Provides Business Update
7:15am
8-K
k7iqs1 x9
3 May 21
AVROBIO Provides Regulatory Update on Investigational AVR-RD-01
7:24am
8-K
nwkgm
23 Mar 21
Regulation FD Disclosure
8:03am
8-K
j82h nz7jf7rxnabxq6
18 Mar 21
AVROBIO Reports Fourth Quarter and Fiscal Year 2020 Financial Results and Provides Business Update
7:06am
8-K
bn0bneea m5onj3
8 Feb 21
Regulation FD Disclosure
7:57am
8-K
kuxumjtpa2e
11 Jan 21
Regulation FD Disclosure
7:01am
8-K
ga5dx2p29v
20 Nov 20
AVROBIO Announces Proposed Public Offering of Common Stock
4:08pm